Literature DB >> 35000013

Paraneoplastic neurological syndromes associated with non-Hodgkin lymphoma: a case series.

Alessandro Dinoto1, Marta Cheli2, Mauro Catalan2, Sasha Olivo2, Ilario Scali2, Claudio Bertolotti2, Arianna Sartori2, Paolo Manganotti2.   

Abstract

BACKGROUND: Paraneoplastic neurological syndromes (PNS) associated with lymphoma are rare diseases that usually have different peculiar features when compared to PNS associated with solid neoplasms.
METHODS: We retrospectively identified patients with NHL-associated PNS. Clinical and demographic data are reported.
RESULTS: We report two cases of NHL-associated PNS: a 72-years old female that presented with rapidly progressive cerebellar syndrome (RCPS) and a 65-years old male that presented with encephalomyelitis (confusion, sensory neuropathy, lower motor neuron involvement). Both PNS were associated with a NHL, small lymphocytic lymphoma and nodal marginal zone lymphoma respectively, and onconeural antibodies tested negative. All patients received first-line immunotherapy with absent or minimal benefit and died of intercurrent infection before cancer or immunosuppressive treatment. DISCUSSION: RCPS and encephalomyelitis rarely present in association with NHL. In our cases, those syndromes took place in the setting of non-aggressive advanced hematological disorders, had an unfavorable prognosis with minimal benefit from immunotherapy, and were seronegative for onconeural antibodies. Our patients fulfilled the criteria for "definite PNS" in the 2004 PNS criteria, but they would be classified as "probable", in the new 2021 PNS criteria. The newest criteria rely on onconeural antibodies testing and on the evidence of antigen expression in cancer cells, features that are usually absent in NHL-associated PNS. New antibodies are being discovered but are still not available to promptly test yet.
CONCLUSION: NHL-associated PNS are rare and bear unfavorable prognosis. The diagnosis should not be overlooked even in seronegative patients.
© 2021. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Encephalomyelitis; Lymphoma; Paraneoplastic neurological syndrome; Rapidly progressive cerebellar syndrome

Mesh:

Substances:

Year:  2022        PMID: 35000013     DOI: 10.1007/s10072-021-05801-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  9 in total

1.  Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease.

Authors:  F Bernal; S Shams'ili; I Rojas; R Sanchez-Valle; A Saiz; J Dalmau; J Honnorat; P Sillevis Smitt; F Graus
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

2.  Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome.

Authors:  E Lancaster; E Martinez-Hernandez; M J Titulaer; M Boulos; S Weaver; J-C Antoine; E Liebers; C Kornblum; C G Bien; J Honnorat; S Wong; J Xu; A Contractor; R Balice-Gordon; J Dalmau
Journal:  Neurology       Date:  2011-10-19       Impact factor: 9.910

3.  Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome.

Authors:  Alberto Vogrig; Bastien Joubert; Aurélien Maureille; Laure Thomas; Emilien Bernard; Nathalie Streichenberger; Francois Cotton; Francois Ducray; Jérome Honnorat
Journal:  J Neurol       Date:  2018-11-29       Impact factor: 4.849

4.  Spectrum of paraneoplastic disease associated with lymphoma.

Authors:  C Briani; R Vitaliani; W Grisold; J Honnorat; F Graus; J C Antoine; G Bertolini; B Giometto
Journal:  Neurology       Date:  2011-02-22       Impact factor: 9.910

5.  Motor neuron disease as a treatment responsive paraneoplastic neurological syndrome in patient with small cell lung cancer, anti-Hu antibodies and limbic encephalitis.

Authors:  Marta Cheli; Alessandro Dinoto; Mariana Ridolfi; Arianna Sartori; David Stokelj; Paolo Manganotti
Journal:  J Neurol Sci       Date:  2019-03-27       Impact factor: 3.181

6.  DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients.

Authors:  William Oliver Tobin; Vanda A Lennon; Lars Komorowski; Christian Probst; Stacey Lynn Clardy; Allen J Aksamit; Juan Pablo Appendino; Claudia F Lucchinetti; Joseph Y Matsumoto; Sean J Pittock; Paola Sandroni; Maja Tippmann-Peikert; Elaine C Wirrell; Andrew McKeon
Journal:  Neurology       Date:  2014-10-15       Impact factor: 9.910

7.  Tumor-specific killer cells in paraneoplastic cerebellar degeneration.

Authors:  M L Albert; J C Darnell; A Bender; L M Francisco; N Bhardwaj; R B Darnell
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

Review 8.  Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas.

Authors:  Francesc Graus; Helena Ariño; Josep Dalmau
Journal:  Blood       Date:  2014-04-04       Impact factor: 22.113

9.  Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes.

Authors:  Alexander Carvajal-González; M Isabel Leite; Patrick Waters; Mark Woodhall; Ester Coutinho; Bettina Balint; Bethan Lang; Philippa Pettingill; Aisling Carr; Una-Marie Sheerin; Rayomand Press; Raomand Press; Michael P Lunn; Ming Lim; Paul Maddison; H-M Meinck; Wim Vandenberghe; Angela Vincent
Journal:  Brain       Date:  2014-06-20       Impact factor: 13.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.